Heart Test Laboratories Announces Management Changes

Heart Test Laboratories (“HTL”) is pleased to announce it has added new key management team members as it prepares to launch the MyoVista to the market. Andrew Simpson has been appointed Executive Chairman and Mark Hilz has been appointed CEO. They join HTL to lead the company as it transitions from a development company to a full service medical device business with manufacturing and sales operations. - July 25, 2013

Heart Test Laboratories Announces MyoVista Production

Heart Test Laboratories, developer of the MyoVista Heart screening device, is pleased to announce the transition from product development to manufacturing. Based on the results of clinical studies involving 40 beta units over the past two years, a final configuration of the MyoVista, hardware and... - March 03, 2013

Heart Test Labs Clinical Trial Within the Canadian Healthcare System

Heart Test Laboratories, Inc., Colleyville, Texas has entered into a Clinical trial to investigate the early detection of cardiovascular disease and structural abnormalities of the heart with a Canadian Aboriginal population. This trial is being conducted at the Southwest Ontario Aboriginal Health Access Center with the Principal Investigator, Dr. M. Vreugdenhil and Co-Investigator, Dr. M. Weingert. - February 28, 2013

Heart Test Laboratories Announces New Board Member, Wilson Rondini

Heart Test Laboratories is pleased to announce the appointment of Wilson Rondini to the company's board of directors. - April 15, 2011

Heart Test Labs Announced Today the Acceptance by the American Society of Echocardiography of a Clinical Trial Abstract Utilizing Their MyoVista Technology

Heart Test Laboratories MyoVista technology has been accepted as an abstract by the American Society of Echocardiography. It is noted that these results provide continuing evidence that the MyoVista™ technology will be a superior diagnostic tool over conventional ECG. The MyoVista provided... - March 02, 2011

Heart Test Laboratories MyoVista™ System Awarded European CE Mark for Heart Disease Screening

Heart Test Laboratories, Inc. today announced that the MyoVista™, its medical screening system which detects Myocardial abnormalities, has been awarded the CE Mark certification by TÜV SÜD. The CE mark (Conformité Européenne) is a mandatory European marking for certain product groups to indicate conformity with essential health and safety requirements. - September 25, 2010

$1.8 Million Dollars in Private Placement Has Been Completed for Texas Based Heart Test Laboratories, Maker of the MyoVista System

Heart Test Labs is pleased to announce the successful and fully subscribed completion of a Private Placement in the amount of $1.8 Million Dollars. - September 05, 2009

Heart Test Labs Announces Interim Corporate Headquarters in Dallas Fort Worth Metroplex

Heart Test Labs Announced today their move to a corporate headquarters located in Colleyville, Texas. "With the success of our clinical trials and preliminary funding, we are now able to expand our operations in anticipation of future growth", said Drew Diaz, Heart Test Lab's CEO. - August 16, 2009

Cardiac Screening Company, Heart Test Laboratories, Names Richard Gray MD as It's U.S. Clinical Advisor

Heart Test Labs, inventors of the non-invasive Myo-Vista Cardiac Screening System(TM), is pleased to announce the addition of Dr Richard Gray M.D., FACC, FAHA as it's United States based Clinical Advisor. Dr Gray is currently the American Heart Association's Western States Affiliate President-Elect. - June 20, 2009

Press Releases 1 - 9 of 9